KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Enterprise Value (2016 - 2025)

Historic Enterprise Value for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to -$1.9 billion.

  • CRISPR Therapeutics AG's Enterprise Value rose 102.99% to -$1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 billion, marking a year-over-year increase of 102.99%. This contributed to the annual value of -$1.9 billion for FY2024, which is 1240.53% down from last year.
  • CRISPR Therapeutics AG's Enterprise Value amounted to -$1.9 billion in Q3 2025, which was up 102.99% from -$1.7 billion recorded in Q2 2025.
  • CRISPR Therapeutics AG's 5-year Enterprise Value high stood at -$1.7 billion for Q4 2023, and its period low was -$2.6 billion during Q2 2021.
  • Its 5-year average for Enterprise Value is -$2.0 billion, with a median of -$1.9 billion in 2024.
  • Its Enterprise Value has fluctuated over the past 5 years, first crashed by 17399.57% in 2021, then soared by 2369.82% in 2022.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Enterprise Value stood at -$2.4 billion in 2021, then rose by 23.7% to -$1.8 billion in 2022, then grew by 6.7% to -$1.7 billion in 2023, then fell by 12.41% to -$1.9 billion in 2024, then decreased by 0.62% to -$1.9 billion in 2025.
  • Its Enterprise Value was -$1.9 billion in Q3 2025, compared to -$1.7 billion in Q2 2025 and -$1.9 billion in Q1 2025.